Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics

Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics

2009-2023

The global market for ophthalmic pharmaceuticals is a large and profitable segment of the healthcare market, with ophthalmic sales of over $10bn in 2007. The recent therapeutic and commercial success of Lucentis has increased the number of blockbuster ophthalmic drugs and highlighted the lucrative commercial rewards on offer in this sector. Which will be the blockbusters of the future? This cutting-edge visiongain report provides the answer - and other essential information that you need to understand the ophthalmic pharmaceutical sector.

"In 15 years, I expect there will be one or more neuroprotective drugs on the market," says a leading expert, interviewed for this visiongain report - Ophthalmic Pharmaceuticals, 2009-2023. The report identifies these future blockbuster drugs and goes on to reveal two currently-untreatable or recalcitrant therapeutic areas with significant unmet need and greatest potential for market growth.

Ophthalmic Pharmaceuticals, 2009-2023 - provides an in-depth analysis of the ophthalmic market, using a wealth of research tools - including sales forecasting, qualitative analyses, probing interviews with industry experts, literature searches and use of commercial databases. The report is packed with original data in tables, charts and other formats.

Visiongain predicts that the global ophthalmic pharmaceutical market will grow steadily from 2009-2023, driven by increasing prevalence of ophthalmic disorders amongst an expanding population of older people. In some countries the market will expand rapidly in coming years, whilst in others the market will stagnate. By purchasing this report, you will find out by how much the ophthalmic market will grow and which countries will achieve most rapid sales growth.

Highlights of Ophthalmic Pharmaceuticals, 2009-2023 include:

• Forecasts for the global ophthalmic market, key therapeutic categories and leading brands from 2009 to 2023
• Expert opinion from key-opinion leaders in the ophthalmic pharmaceutical sector
• Examination of strengths, weakness, opportunities and threats (SWOT) facing major stakeholders in that industrial sector
• In-depth analysis of the ophthalmic pharmaceutical pipeline
• Analysis and forecasts for the principal national markets, including the US, Japan, Brazil, India, China and leading European markets.

Why you should buy this report:

• To receive a comprehensive analysis of the prospects for ophthalmic drugs, including key metrics and predicted revenues, by therapeutic category and brand
• To discover the forces, restraints, competition and opportunities influencing each of the separate ophthalmic markets, including anti-glaucoma, retinal disorder, dry eye and ophthalmic allergy, inflammation and infection
• To read the views of experts in the industry, regarding current and future trends, opportunities and drivers. The report includes full transcripts of interviews - information that you will not find anywhere else
• To find out how the ophthalmic pharmaceutical market is progressing worldwide - both technologically and commercially

This visiongain report provides a comprehensive pipeline analysis showing how a range of drugs - from simple anti-infective agents to advanced molecular treatments - combined with a wider range of drug delivery systems should aid the restoration of vision or the cessation of vision loss.

Success in the ophthalmic pharmaceutical market from 2008 to 2023 will be characterised by the launch of products with superior efficacy, safety and tolerability. Ophthalmic Pharmaceuticals, 2009-2023 shows how emerging technologies that increase clinical effectiveness and/or increase patient compliance will be particularly important therapeutically and commercially.

Contents

• 1 Executive Summary
• 2 Ophthalmic Disorders and Treatments
  • 2.1 The Ophthalmology Market
  • 2.2 Ophthalmic Disorders
  • 2.3 The Human Eye and the Vision Process
  • 2.4 Glaucoma
    • 2.4.1 Primary Open Angle Glaucoma: The Most Common Type of Glaucoma
    • 2.4.2 Closed Angle Glaucoma
    • 2.4.3 Secondary Glaucoma
    • 2.4.4 Congenital Glaucoma
    • 2.4.5 Normal Tension Glaucoma
    • 2.4.6 Ocular Hypertension
    • 2.4.7 Glaucoma Risk Factors
    • 2.4.8 Diagnosis of Glaucoma
    • 2.4.9 Prevalence of Glaucoma
    • 2.4.10 Treatment of Glaucoma
    • 2.4.11 Prostaglandins are the First-Line Treatment of Choice
    • 2.4.12 Second-Line Glaucoma Treatments
    • 2.4.13 Combination Treatments
    • 2.4.14 Laser Treatment
    • 2.4.15 Surgery (Trabeculectomy)
  • 2.5 Age-Related Macular Degeneration (AMD)
    • 2.5.1 Dry AMD
    • 2.5.2 Wet AMD
    • 2.5.3 AMD Risk Factors
    • 2.5.4 Diagnosis of AMD
    • 2.5.5 Prevalence of AMD
    • 2.5.6 Treatment of AMD
  • 2.6 Diabetic Retinopathy
    • 2.6.1 Diagnosis of Diabetic Retinopathy
    • 2.6.2 Prevalence of Diabetic Retinopathy
    • 2.6.3 Laser and Surgical Treatments are the Main Treatments for Diabetic Retinopathy
    • 2.6.4 Pharmaceutical Treatments
  • 2.7 Ophthalmic Allergies
    • 2.7.1 Allergic Conjunctivitis is the Most Common Eye Allergy
    • 2.7.2 Ophthalmic Allergy Treatments
  • 2.8 Ophthalmic Inflammatory Disorders
    • 2.8.1 Uveitis is the Most Common Ocular Inflammatory Disease
    • 2.8.2 Ophthalmic Inflammatory Drugs
  • 2.9 Ophthalmic Infections
    • 2.9.1 Types of Eye Infection
    • 2.9.2 Treatment of Eye Infections
  • 2.10 Dry Eye Syndrome
    • 2.10.1 Causes and Prevalence of Dry Eye Syndrome
    • 2.10.2 The Mainstay of Dry Eye Treatment is Artificial Tears
    • 2.10.3 Prescription-Only Drugs for Dry Eye are Limited
    • 2.10.4 Tear Augmenters (Punctal Plugs)
• 3 The Global Ophthalmic Pharmaceutical Market, 2008-2023
  • 3.1 The Ophthalmic Pharmaceutical Market in 2007
    • 3.1.1 Anti-Glaucoma had Largest Market Share in 2007
    • 3.1.2 Top Twelve Ophthalmic Pharmaceutical Brands, 2007
    • 3.1.3 Three Manufacturers Account for Almost Half the Market
  • 3.2 Global Ophthalmic Pharmaceutical Market Forecasts, 2008-2023
    • 3.2.1 Generic Competition in the Ophthalmic Pharmaceutical Market during 2008-2013
    • 3.2.2 What are the Prospects for the Ophthalmic Pharmaceutical Market during 2013-2023?
  • 3.3 Ophthalmic Pharmaceutical Therapeutic Category Market Forecasts, 2008-2023
    • 3.3.1 Two Therapeutic Categories Will Power Growth during 2008-2013
    • 3.3.2 Retinal Disorder Drug Growth Will Continue Through 2013-2018
    • 3.3.3 High Growth and Return to Market-Leading Position for Anti-Glaucoma during 2018-2023
• 4 The Anti-Glaucoma Market, 2008-2023
  • 4.1 The Anti-Glaucoma Market in 2007
    • 4.1.1 Prostaglandin Analogues Lead the Anti-Glaucoma Market in 2007
    • 4.1.2 Xalatan/Xalacom
    • 4.1.3 Cosopt/Trusopt
    • 4.1.4 Travatan/Travatan Z/DuoTrav
    • 4.1.5 Lumigan/Ganfort
    • 4.1.6 Alphagan/Combigan
    • 4.1.7 Azopt
  • 4.2 Anti-Glaucoma Market Forecasts, 2008-2023
    • 4.2.1 Generic Competition Will Impact Anti-Glaucoma Market During 2008-2013
    • 4.2.2 Novel Glaucoma Drugs Will Drive Growth during 2013-2023
    • 4.2.3 Xalatan/Xalacom Sales Forecast, 2008-2023
    • 4.2.4 Cosopt/Trusopt Sales Forecast, 2008-2023
    • 4.2.5 Travatan/Travatan Z/DuoTrav Sales Forecast, 2008-2023
    • 4.2.6 Lumigan/Ganfort Sales Forecast, 2008-2023
    • 4.2.7 Alphagan/Combigan Sales Forecast, 2008-2023
    • 4.2.8 Azopt/Azarga Sales Forecast, 2008-2023
• 5 The Ophthalmic Anti-Allergy/Inflammatory/Infective Market, 2008-2023
  • 5.1 The Ophthalmic Anti-Allergy/Inflammatory/Infective Market in 2007
    • 5.1.1 Patanol/Opatanol/Pataday
    • 5.1.2 TobraDex
    • 5.1.3 Vigamox/Vegamox
  • 5.2 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecasts, 2008-2023
    • 5.2.1 Lack of Novel Pipeline Products in Anti-Allergy/Inflammatory/Infective Sector
    • 5.2.2 Patanol/Opatanol/Pataday Sales Forecast, 2008-2023
    • 5.2.3 TobraDex Sales Forecast, 2008-2023
    • 5.2.4 Vigamox/Vegamox Sales Forecast, 2008-2023
• 6 The Retinal Disorder Market, 2008-2023
  • 6.1 The Retinal Disorder Market in 2007
    • 6.1.1 Wet AMD has the Largest Market Share of the Retinal Disorder Market
    • 6.1.2 Lucentis Took Control of the Retinal Disorder Market in 2007
    • 6.1.3 Visudyne was the Second Highest-Selling Retinal Disorder Drug in 2007
    • 6.1.4 Lucentis has Side-Lined Macugen but Faces Potent Threat from Avastin
    • 6.1.5 The Diabetic Retinopathy Market
  • 6.2 Retinal Disorder Market Forecasts, 2008-2023
    • 6.2.1 Lucentis Will Drive the Retinal Disorder Market during 2008-2013
    • 6.2.2 Novel Drugs and New Disease Treatments will Drive Growth during 2013-2023
    • 6.2.3 Lucentis Sales Forecast, 2008-2023
    • 6.2.4 Visudyne Sales Forecast, 2008-2023
• 7 The Dry Eye Market, 2008-2023
  • 7.1 The Dry Eye Market in 2007
    • 7.1.1 Restasis is the Only Prescription-Only Drug for Dry Eye in the US
    • 7.1.2 Hyalein: Marketed in Japan and China
    • 7.1.3 The OTC Market for Artificial Tears is Fragmented and Competitive
  • 7.2 Dry Eye Market Forecasts, 2008-2023
    • 7.2.1 Increased Sales of Dry Eye Prescription Drugs Forecasted During 2008-2013
    • 7.2.2 Growth in the Dry Eye Market Will Moderate After 2013
    • 7.2.3 Restasis Sales Forecast, 2008-2023
• 8 Issues Affecting the Market for Ophthalmic Pharmaceuticals
  • 8.1 SWOT Analysis of the Ophthalmic Pharmaceutical Market
  • 8.2 Strengths in the Ophthalmic Pharmaceutical Market
    • 8.2.1 Development of New Drug Delivery Methods and Formulations
    • 8.2.2 Intraocular Injections
    • 8.2.3 Sustained-Release Ocular Implants
    • 8.2.4 Gene Therapy and RNA Interference Technology
    • 8.2.5 New Ophthalmic Therapeutic Applications for Drugs
    • 8.2.6 Development of Neuroprotective Anti-Glaucoma Medications
  • 8.3 Weaknesses in the Ophthalmic Pharmaceutical Market
    • 8.3.1 The Ophthalmic Pharmaceutical Market Will Face Generic Competition
    • 8.3.2 Avastin is Cannibalising Lucentis' Revenues
  • 8.4 Opportunities for the Ophthalmic Pharmaceutical Market
    • 8.4.1 The Greying of the World Population
    • 8.4.2 Increasing Prevalence of Diabetes and Unhealthy Lifestyles
    • 8.4.3 Increasing Prevalence of Eye Disorders
    • 8.4.4 Retinal Disorders Will Have the Most Marked Increases in Prevalence
    • 8.4.5 Increasing Prevalence of Glaucoma, Dry Eye and Other Ophthalmic Disorders
    • 8.4.6 Generous Reimbursement for Ophthalmic Pharmaceuticals
  • 8.5 Threats Facing the Ophthalmic Pharmaceutical Market
    • 8.5.1 Poor Patient Compliance
    • 8.5.2 The Rate of Diagnosis for Eye Disorders is Low
• 9 Ophthalmic Pharmaceutical Country Markets
  • 9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2007
  • 9.2 Leading Developed Country Ophthalmic Pharmaceutical Markets, 2008-2023
    • 9.2.1 The US Ophthalmic Pharmaceutical Market
    • 9.2.2 The Japanese Ophthalmic Pharmaceutical Market
    • 9.2.3 European Ophthalmic Pharmaceutical Markets
  • 9.3 Emerging Economy Ophthalmic Pharmaceutical Market Forecasts, 2008-2023
    • 9.3.1 Ophthalmic Pharmaceuticals are Making the Leap to Developing Countries
    • 9.3.2 The Indian Ophthalmic Pharmaceutical Market
    • 9.3.3 The Chinese Ophthalmic Pharmaceutical Market
• 10 The Ophthalmic Pharmaceutical Pipeline
  • 10.1 The Ophthalmic Pharmaceutical Pipeline: Richest in Anti-Glaucoma and Retinal Disorder Drugs
  • 10.2 The Anti-Glaucoma Pipeline
    • 10.2.1 Neuroprotection Will Be the Most Important Anti-Glaucoma Pipeline Development
    • 10.2.2 Taflotan/DE-085 (Santen/Asahi)
    • 10.2.3 Azarga (Alcon)
    • 10.2.4 Anecortave (Alcon)
    • 10.2.5 DNB-001 (Danube)
    • 10.2.6 BVT.28949 (Biovitrum)
    • 10.2.7 DE-092/Olmesarten (Santen)
    • 10.2.8 OT-730 (Othera)
    • 10.2.9 AL-37807 (Alcon)
    • 10.2.10 PF-4217329 (Pfizer)
    • 10.2.11 QLT's Punctal Plug Delivery Technology
    • 10.2.12 PF-03187207 (NicOx/Pfizer)
  • 10.3 The Ophthalmic Anti-Allergy Pipeline
    • 10.3.1 Bepreve (ISTA/Senju)
    • 10.3.2 FOV1101 (Fovea/CombinatoRx)
    • 10.3.3 DE-103 (Santen)
  • 10.4 The Ophthalmic Anti-Inflammatory Pipeline
    • 10.4.1 T-Pred (ISTA)
    • 10.4.2 AzaSite Plus/ASV-502 (InSite Vision)
    • 10.4.3 Durezol (Senju/Sirion Therapeutics)
    • 10.4.4 Luveniq (LuxBiosciences)
    • 10.4.5 Simulect (Cerimon)
    • 10.4.6 EGP-437 (EyeGatePharm)
  • 10.5 The Ophthalmic Anti-Infective Pipeline
    • 10.5.1 TobraDex ST (Alcon)
    • 10.5.2 ISV-403 (Besifloxacin, Bausch & Lomb)
    • 10.5.3 Moxifloxacin/Dexamethasone (Alcon)
  • 10.6 The Retinal Disease Pipeline
    • 10.6.1 Retinal Diseases Have the Richest Pipeline
    • 10.6.2 Arxxant (Eli Lilly/Alcon/Takeda)
    • 10.6.3 Vitrase/Vitragen (ISTA)
    • 10.6.4 Aflibercept/VEGF Trap-Eye (Regeneron/Bayer)
    • 10.6.5 Bevasiranib/Cand5 (Opko)
    • 10.6.6 Lucentis (Genentech/Roche/Novartis)
    • 10.6.7 Atacand/TCV-116 (AstraZeneca/Takeda)
    • 10.6.8 SNK-860 (Sanwa Kagaku Kenkyusho)
    • 10.6.9 Posurdex/SK-0503 (Allergan/Sanwa Kagaku Kenkyusho)
    • 10.6.10 Medidur (pSivida/Alimera Sciences/Pfizer)
    • 10.6.11 NT-501 (Neurotech)
    • 10.6.12 Microplasmin (ThromboGenics)
    • 10.6.13 Sustained-Release Brimonidine (Allergan)
    • 10.6.14 RTP801i-14/PF-4523655 (Quark/Pfizer)
    • 10.6.15 AGN-745/SIRNA-027 (Allergan/Merck & Co.)
    • 10.6.16 ATG-3 (CoMentis)
    • 10.6.17 OT-551 (Othera)
    • 10.6.18 Fenretinide (Sirion Therapeutics)
    • 10.6.19 RPE65 Gene Therapy (Targeted Genetics)
  • 10.7 The Dry Eye Pipeline
    • 10.7.1 Prolacria (Inspire/Allergan/Santen)
    • 10.7.2 Cyclosporine Ophthalmic Solution (Sirion Therapeutics)
    • 10.7.3 Rebamipide (Otsuka/Acucela)
    • 10.7.4 DE-101/Rivoglitazone (Santen)
    • 10.7.5 Ecabet (ISTA)
  • 10.8 The Pipeline for Other Ophthalmic Indications Includes Eyelash Growth-Stimulators
• 11 Expert Views from Key-Opinion Leaders
  • 11.1 Barrett Katz, M.D., M.B.A., Chief Executive Officer and Chief Medical Officer and Brian Levy, O.D., M.Sc., Chief Operating Officer, Danube Pharmaceuticals
    • 11.1.1 Neuroprotection is the Key Unmet Need Amongst Glaucoma Patients
    • 11.1.2 Danube's Pipeline Anti-Glaucoma Medication: DNB-001
    • 11.1.3 Key Threats Facing the Ophthalmic Pharmaceutical Industry
    • 11.1.4 Major Growth Opportunities in the Ophthalmic Pharmaceutical Industry
    • 11.1.5 The Future of the Anti-Glaucoma Market
  • 11.2 Dr Al Reaves, Ph.D., Senior Vice President of Clinical Development, Othera Pharmaceuticals
    • 11.2.1 Which Areas of the Ophthalmic Pharmaceutical Industry will have Greatest Growth?
    • 11.2.2 Othera's Geographic Atrophy Drug: OT-551
    • 11.2.3 How Will Glaucoma be Treated in 2023?
    • 11.2.4 Othera's Neuroprotective Anti-Glaucoma Drug: OT-440
    • 11.2.5 Othera's New Generation Beta Blocker: OT-730
    • 11.2.6 New Drugs for Ophthalmic Conditions Currently with No Treatments
• 12 Conclusions
  • 12.1 The Ophthalmic Pharmaceutical Market in 2007
  • 12.2 Visiongain's Ophthalmic Pharmaceutical Market Forecast, 2008-2023
  • 12.3 Who Will Succeed in the Ophthalmic Pharmaceutical Marketplace?
  • 12.4 Where Will the Ophthalmic Pharmaceutical Market Grow Fastest?
• List of Tables
  • Table 2.1 Major Glaucoma Pharmaceutical Types
  • Table 2.2 Major AMD Drugs
  • Table 2.3 Ophthalmic Allergy Drug Types
  • Table 2.4 Ophthalmic Inflammatory Disorder Drug Types
  • Table 2.5 Key Ophthalmic Anti-Infective Drug Types
  • Table 3.1 Ophthalmic Pharmaceutical Therapeutic Category Market Share, 2007
  • Table 3.2 Top-Twelve Ophthalmic Pharmaceutical Brands, 2007
  • Table 3.3 Top-Eight Ophthalmic Pharmaceutical Manufacturers, 2007
  • Table 3.4 Global Ophthalmic Pharmaceutical Market Forecast, 2008-2013
  • Table 3.5 Global Ophthalmic Pharmaceutical Market Forecast, 2014-2023
  • Table 3.6 Ophthalmic Pharmaceutical Therapeutic Category Forecast, 2008-2013
  • Table 3.7 Ophthalmic Pharmaceutical Therapeutic Category Forecast, 2014-2023
  • Table 4.1 Leading Anti-Glaucoma Brands, 2007
  • Table 4.2 World Anti-Glaucoma Market Forecast, 2008-2013
  • Table 4.3 World Anti-Glaucoma Market Forecast, 2014-2023
  • Table 4.4 Leading Anti-Glaucoma Brands Sales Forecast, 2008-2013
  • Table 4.5 Leading Anti-Glaucoma Brands Sales Forecast, 2014-2023
  • Table 5.1 Therapeutic Category Market Share in the Ophthalmic Anti-Allergy/Inflammatory/Infective Market, 2007
  • Table 5.2 Leading Anti-Allergy/Inflammatory/Infective Brands, 2007
  • Table 5.3 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecast, 2008-2013
  • Table 5.4 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecast, 2014-2023
  • Table 5.5 Leading Anti-Allergy/Inflammatory/Infective Brand Sales Forecast, 2008-2013
  • Table 5.6 Leading Anti-Allergy/Inflammatory/Infective Brand Sales Forecast, 2014-2023
  • Table 6.1 Therapeutic Category Market Share in the Retinal Disorder Market, 2007
  • Table 6.2 Leading Retinal Disorder Brands, 2007
  • Table 6.3 World Retinal Disorder Market Forecast, 2008-2013
  • Table 6.4 World Retinal Disorder Market Forecast, 2014-2023
  • Table 6.5 Leading Retinal Disorder Brands Sales Forecast, 2008-2013
  • Table 6.6 Leading Retinal Disorder Brands Sales Forecast, 2014-2023
  • Table 7.1 Leading Dry Eye Brands, 2007
  • Table 7.2 World Dry Eye Market Forecast, 2008-2013
  • Table 7.3 World Dry Eye Market Forecast, 2014-2023
  • Table 7.4 Restasis Sales Forecast, 2008-2013
  • Table 7.5 Restasis Sales Forecast, 2014-2023
  • Table 8.1 SWOT Chart for the Ophthalmic Pharmaceutical Market
  • Table 8.2 Expected Patent Expiries for Leading Ophthalmic Pharmaceuticals, 2008-2014
  • Table 8.3 Global Ophthalmic Disorder Prevalence Forecast, 2007-2030
  • Table 9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2007
  • Table 9.2 Leading Ophthalmic Pharmaceutical Country Market Forecasts, 2008-2013
  • Table 9.3 Leading Ophthalmic Pharmaceutical Country Market Forecasts, 2014-2023
  • Table 10.1 Key Drugs in the Anti-Glaucoma Pipeline
  • Table 10.2 Key Drugs in the Ophthalmic Anti-Allergy Pipeline
  • Table 10.3 Key Drugs in the Ophthalmic Anti-Inflammatory Pipeline
  • Table 10.4 Key Drugs in the Ophthalmic Anti-Infective Pipeline
  • Table 10.5 Key Drugs in the Retinal Disease Pipeline: 1
  • Table 10.6 Key Drugs in the Retinal Disease Pipeline: 2
  • Table 10.7 Key Drugs in the Dry Eye Pipeline
  • Table 10.8 Key Pipeline Drugs for Other Ophthalmic Indications
• List of Figures
  • Figure 3.1 Ophthalmic Pharmaceutical Therapeutic Category Market Share, 2007
  • Figure 3.2 Top-Eight Ophthalmic Pharmaceutical Manufacturers, 2007
  • Figure 3.3 Global Ophthalmic Pharmaceutical Market Forecast, 2008-2023
  • Figure 3.4 Ophthalmic Pharmaceutical Therapeutic Category Market Share and Forecast, 2008-2023
  • Figure 3.5 Ophthalmic Pharmaceutical Therapeutic Category Forecast, 2008-2023
  • Figure 4.1 Leading Anti-Glaucoma Brands, 2007
  • Figure 4.2 World Anti-Glaucoma Market Forecast, 2008-2023
  • Figure 4.3 Leading Anti-Glaucoma Brands, 2013
  • Figure 4.4 Xalatan/Xalacom Sales Forecast, 2008-2023
  • Figure 4.5 Cosopt/Trusopt Sales Forecast, 2008-2023
  • Figure 4.6 Travatan/Travatan Z/DuoTrav Sales Forecast, 2008-2023
  • Figure 4.7 Lumigan/Ganfort Sales Forecast, 2008-2023
  • Figure 4.8 Alphagan/Combigan Sales Forecast, 2008-2023
  • Figure 4.9 Azopt/Azarga Sales Forecast, 2008-2023
  • Figure 5.1 Therapeutic Category Market Share in the Ophthalmic Anti-Allergy/Inflammatory/Infective Market, 2007
  • Figure 5.2 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecast, 2008-2023
  • Figure 5.3 Patanol/Opatanol/Pataday Sales Forecast, 2008-2023
  • Figure 5.4 TobraDex Sales Forecast, 2008-2023
  • Figure 5.5 Vigamox/Vegamox Sales Forecast, 2008-2023
  • Figure 6.1 Therapeutic Category Market Share in the Retinal Disorder Market, 2007
  • Figure 6.2 Leading Retinal Disorder Brands, 2007
  • Figure 6.3 World Retinal Disorder Market Forecast, 2008-2023
  • Figure 6.4 Lucentis Sales Forecast, 2008-2023
  • Figure 6.5 Visudyne Sales Forecast, 2008-2023
  • Figure 7.1 World Dry Eye Market Forecast, 2008-2023
  • Figure 7.2 Restasis Sales Forecast, 2008-2023
  • Figure 8.1 Global Population Aged Over 65, 2007-2023
  • Figure 8.2 Population Aged 65 Years or Over in Major Ophthalmic Pharmaceutical Country Markets, 2007 and 2023
  • Figure 8.3 Global Prevalence of Diabetes and Diabetic Retinopathy, 2007 and 2030
  • Figure 9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2007
  • Figure 9.2 Leading Ophthalmic Pharmaceutical Country Markets, 2013
  • Figure 9.3 Leading Ophthalmic Pharmaceutical Country Markets, 2018
  • Figure 9.4 Leading Ophthalmic Pharmaceutical Country Markets, 2023
  • Figure 9.5 US and Japanese Ophthalmic Pharmaceutical Market Forecasts, 2008-2023
  • Figure 9.6 European, Brazilian, Indian and Chinese Ophthalmic Pharmaceutical Market Forecasts, 2008-2023
  • Figure 12.1 Global Ophthalmic Pharmaceutical Market Forecast, 2008-2023
• Companies Listed
  • Acucela
  • Alcon (Nestl)
  • Alimera Sciences
  • Allergan
  • American Academy of Ophthalmology (AAO) [US]
  • American Society of Retinal Specialists (ASRS) [US]
  • Asahi
  • AstraZeneca
  • Bausch & Lomb
  • Bayer
  • Biovitrum
  • Can-Fite
  • Cerimon
  • Chugai
  • CombinatoRx
  • CoMentis
  • Danube
  • Eli Lilly
  • Esteve
  • European Medicines Agency (EMEA)
  • EyeGate
  • Food and Drug Administration (FDA) [US]
  • Fovea
  • Genentech
  • GSK
  • InSite Vision
  • Inspire
  • ISTA Pharmaceuticals
  • Kowa
  • Kyowa Hakko Kirin
  • Laborotorios Sophia [Mexico]
  • LEO Pharma
  • LuxBiosciences
  • Meda
  • Merck & Co.
  • Ministry of Health, Labour and Welfare [Japan]
  • Moorfields Eye Hospital [UK]
  • National Eye Institute (NEI) [US]
  • National Institute for Health and Clinical Excellence (NICE) [UK]
  • National Institutes of Health (NIH) [US]
  • Neurotech
  • NicOx
  • Novartis
  • Opko
  • OSI Pharmaceuticals
  • Othera
  • Otsuka
  • Pfizer
  • pSivida
  • QLT
  • Quark
  • Regeneron
  • Roche
  • Santen
  • Sanwa Kagaku Kenkyusho
  • Senju
  • Sirion Therapeutics
  • Takeda
  • Targeted Genetics
  • ThromboGenics
  • University College of London's (UCL) Institute of Ophthalmology [UK]

Related products

Cataract Surgery - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 Cataract Surgery - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 Summary GlobalData's new report, "Cataract Surgery Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016" provides...

Australia Medical Equipment Market Analysis and Forecasts to 2015 GlobalData's "Australia Medical Equipment Market Analysis and Forecasts to 2015" report provides key data, information and analysis on the Australia medical equipment markets. The report provides market landscape, competitive landscape...

Italy Medical Equipment Market Analysis and Forecasts to 2015 GlobalData's ""Italy Medical Equipment Market Analysis and Forecasts to 2015"" report provides key data, information and analysis on the Italy medical equipment markets. The report provides market landscape, competitive landscape...

Saudi Arabia Medical Equipment Market Analysis and Forecasts to 2017 Saudi Arabia Medical Equipment Market Analysis and Forecasts to 2017 Summary GlobalData's new report, "Saudi Arabia Medical Equipment Market Analysis and Forecasts to 2017" provides key data, information and analysis on the...

Canada Medical Equipment Market Analysis and Forecasts to 2016 Canada Medical Equipment Market Analysis and Forecasts to 2016 Summary This report is an essential source for in-depth information and data relating to the Canada medical equipment market. The report provides an...

South African Opthalmology Pharmaceuticals Market This research service provides an insight into the South African Ophthalmology Pharmaceuticals Market. A comprehensive PESTLE (Politic, Economic, Social, Technology, Legal, Environment) analyses provides a strategic assessment of factors in...

The Future of Ophthalmic Devices Market Forecasts and Growth Opportunities to 2016 The Future of Ophthalmic Devices, Market Forecasts and Growth Opportunities to 2016 - The Vision Care Segment Emerges as a Key Revenue Generator Summary GBI Research's report, 'The Future of Ophthalmic Devices,...

Spain Medical Equipment Market Analysis and Forecasts to 2015 GlobalData's ""Spain Medical Equipment Market Analysis and Forecasts to 2015"" report provides key data, information and analysis on the Spain medical equipment markets. The report provides market landscape, competitive landscape...

Japan Medical Equipment Market Analysis and Forecasts to 2015 This report is an essential source for in-depth information and data relating to the Japan medical equipment market. The report provides an overview of the market structure, healthcare system, regulatory...

Opthalmic Pharmaceutical Drugs This report analyzes the worldwide markets for Opthalmic Pharmaceutical Drugs in US$ million by the following Therapeutic Categories: Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye, and Others. The report provides...

Middle East & Africa Ophthalmic/Ophthalmology Devices Industry Report Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Cataract Surgery, Refractive Surgery and Vision Care Equipment, Devices and Supplies This report is an essential source for in-depth information...

Asia Pacific Ophthalmic/Ophthalmology Devices Industry Report Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Cataract Surgery, Refractive Surgery and Vision Care Equipment, Devices and Supplies This report is an essential source for in-depth information...

France Medical Equipment Market Analysis and Forecasts to 2015 This report is an essential source for in-depth information and data relating to the France medical equipment market. The report provides an overview of the market structure, healthcare system, regulatory...

Ophthalmic Therapeutic Drugs Technologies and Global Markets Introduction Study Goals and Objectives The Goals of This Market Research Report Are to Quantify, Forecast and Analyze The Market for Ophthalmic Drugs, and to Provide A Range of Market Information from...

Global Ophthalmic Market: Focus on Glaucoma Glaucoma is a type of disease that causes an irreversible blindness, if it is left undetected or untreated. Moreover there is no cure for glaucoma and regular medication is the...

North America Ophthalmic/Ophthalmology Devices Industry Report Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Cataract Surgery, Refractive Surgery and Vision Care Equipment, Devices and Supplies This report is an essential source for in-depth information...

Markets for Emerging Pharmaceutical Technologies REPORT HIGHLIGHTS As a segment, therapeutic vaccines recorded $19.3 billion in 2010, a figure that is expected to grow to $31.9 billion by 2015, demonstrating a compound annual growth rate (CAGR)...

U.S. Market for Prescription Ophthalmic Drugs, Devices, Diagnostics, and Surgical Equipment, The The aging of the population in the United States will result in a two-fold increase in the 65 and over population by 2030, a population that accounts for the highest...

Ophthalmic Pharmaceutical Drugs A Global Market Perspective Prevention of blindness has emerged into a top health priority among aging citizens in the developed countries. And increased healthcare spending in these countries is creating a strong demand for...

United Kingdom Medical Equipment Market Analysis and Forecasts to 2015 This report is an essential source for in-depth information and data relating to the UK medical equipment market. The report provides an overview of the market structure, healthcare system, regulatory...

Germany Medical Equipment Market Analysis and Forecasts to 2015 This report is an essential source for in-depth information and data relating to the Germany medical equipment market. The report provides an overview of the market structure, healthcare system, regulatory...

South & Central America Ophthalmic/Ophthalmology Devices Industry Report Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Cataract Surgery, Refractive Surgery and Vision Care Equipment, Devices and Supplies This report is an essential source for in-depth information...

The Future of the Medical Equipment Industry The Future of the medical equipment industry report provides key data and information about the global medical equipment industry including market overview, drivers and restraints, future outlook and key pipeline...

United States Medical Equipment Market Analysis & Forecasts to 2015 United States Medical Equipment Market Analysis & Forecasts to 2015 This report is an essential source for in-depth information and data relating to the US medical equipment market. The report provides...

Global Ophthalmic Market Analysis & Forecasts to 2012 Please Note: Reports are sold based on the user licenses indicated. The reports will be accessible in Flash format via an online reading room on the publisher website, allowing viewing...

Ophthalmic Drugs: World Market 2011-2021 Where will the highest revenue growth occur in the ophthalmic drug market? Our new report shows you the eye disorder treatment market's potential from 2011 to 2021. We forecast and...

U.S. Non-Glaucoma Ophthalmic Pharmaceuticals Market This research service explores the market for prescription ophthalmics used for the treatment of ocular diseases such as age-related macular degeneration (AMD), allergic conjunctivitis, chronic dry eye, cataract, and diabetic...

Canada Ophthalmic Devices Investment Opportunities Analysis and Forecasts to 2012 Canada Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2012 Summary This report is an essential source for in-depth information and data relating to the Canada ophthalmic devices market. It also offers...

Europe Ophthalmic/Ophthalmology Devices Industry Report Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Cataract Surgery, Refractive Surgery and Vision Care Equipment, Devices and Supplies This report is an essential source for in-depth information...

Brazil Medical Equipment Market Analysis and Forecasts to 2015 GlobalData's "Brazil Medical Equipment Market Analysis and Forecasts to 2015" report provides key data, information and analysis on the Brazil medical equipment markets. The report provides market landscape, competitive landscape...

View all products in this category